Immunome (IMNM) Short Interest Ratio & Short Volume $10.30 +0.35 (+3.52%) Closing price 04:00 PM EasternExtended Trading$10.30 +0.00 (+0.05%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immunome Short Interest DataImmunome (IMNM) has a short interest of 14.21 million shares, representing 17.91% of the float (the number of shares available for trading by the public). This marks a 0.07% increase in short interest from the previous month. The short interest ratio (days to cover) is 15.2, indicating that it would take 15.2 days of the average trading volume of 1.00 million shares to cover all short positions.Current Short Interest14,210,000 sharesPrevious Short Interest14,200,000 sharesChange Vs. Previous Month+0.07%Dollar Volume Sold Short$149.49 millionShort Interest Ratio15.2 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares87,040,000 sharesFloat Size79,320,000 sharesShort Percent of Float17.91%Today's Trading Volume1,038,865 sharesAverage Trading Volume1,001,085 sharesToday's Volume Vs. Average104% Short Selling Immunome? Sign up to receive the latest short interest report for Immunome and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIMNM Short Interest Over TimeIMNM Days to Cover Over TimeIMNM Percentage of Float Shorted Over Time Immunome Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/202514,210,000 shares $149.49 million +0.1%17.9%15.2 $10.52 7/15/202514,200,000 shares $119.28 million +12.9%18.5%14.1 $8.40 6/30/202512,580,000 shares $116.99 million +0.5%16.4%12 $9.30 6/15/202512,520,000 shares $115.18 million -5.4%16.3%11.3 $9.20 5/31/202513,240,000 shares $117.31 million +4.1%17.2%11.7 $8.86 5/15/202512,720,000 shares $101.76 million -6.8%16.6%11.3 $8.00 4/30/202513,650,000 shares $119.98 million +9.4%17.8%12.4 $8.79 4/15/202512,480,000 shares $92.35 million +12.1%16.6%10.6 $7.40 3/31/202511,130,000 shares $74.90 million +16.9%14.8%10.1 $6.73 3/15/20259,520,000 shares $83.49 million +2.4%12.6%9.8 $8.77 Get the Latest News and Ratings for IMNM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. 2/28/20259,300,000 shares $87.42 million -0.5%13.4%10.3 $9.40 2/15/20259,350,000 shares $97.24 million +3.1%13.4%9.9 $10.40 1/31/20259,070,000 shares $100.04 million -14.0%13.0%9.1 $11.03 1/15/202510,540,000 shares $106.56 million +6.8%20.6%13.1 $10.11 12/31/20249,870,000 shares $104.82 million +12.2%19.2%12.5 $10.62 12/15/20248,800,000 shares $110.70 million -10.1%17.2%11.2 $12.58 11/30/20249,790,000 shares $132.65 million -8.3%19.3%12.4 $13.55 11/15/202410,670,000 shares $105.69 million +1.9%21.0%14.3 $9.91 10/31/202410,470,000 shares $120.09 million -4.1%21.4%17.3 $11.47 10/15/202410,920,000 shares $133.01 million -15.2%22.3%16.8 $12.18 9/30/202412,880,000 shares $188.31 million +3.5%26.3%19.8 $14.62 9/15/202412,440,000 shares $198.67 million -6.4%25.4%16.2 $15.97 8/31/202413,290,000 shares $201.74 million +5.9%27.1%16.5 $15.18 8/15/202412,550,000 shares $175.07 million -8.9%25.6%14.5 $13.95 7/31/202413,780,000 shares $212.35 million +2.4%28.1%14.7 $15.41 7/15/202413,460,000 shares $190.59 million No Change27.5%14.1 $14.16 2/29/20242,650,000 shares $64.13 million -31.2%N/A4.2 $24.20 2/15/20243,850,000 shares $86.70 million +12.9%N/A7.1 $22.52 1/31/20243,410,000 shares $56.50 million +71.4%N/A9.2 $16.57 1/15/20241,990,000 shares $26.19 million +8.2%N/A8.7 $13.16 12/31/20231,840,000 shares $19.69 million +171.4%N/A11.1 $10.70 12/15/2023678,100 shares $5.11 million +24.6%N/A5.1 $7.54 11/30/2023544,100 shares $4.06 million +27.1%N/A7.9 $7.46 11/15/2023428,200 shares $3.40 million +96.4%N/A7.4 $7.95 10/31/2023218,000 shares $1.92 million +10.3%N/A4.6 $8.80 10/15/2023197,700 shares $1.78 million -10.3%N/A4.5 $8.99 9/30/2023220,500 shares $1.84 million -3.0%2.9%4.5 $8.35 9/15/2023227,200 shares $1.65 million +5.3%2.7%0.9 $7.26 8/31/2023215,800 shares $1.39 million +0.1%2.6%0.9 $6.45 8/15/2023215,500 shares $1.61 million -11.7%2.6%0.9 $7.45The Trump Dump is starting; Get out of stocks now? (Ad)The first 365 days of the Trump presidency… Will be the best time to get rich in American history.If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a 7/31/2023244,000 shares $1.75 million +17.4%2.9%1 $7.16 7/15/2023207,800 shares $1.61 million +70.9%2.6%0.8 $7.77 6/30/2023121,600 shares $961.86 thousand -14.9%1.5%0.5 $7.91 6/15/2023142,900 shares $763.09 thousand -3.1%1.5%5 $5.34 5/31/2023147,500 shares $772.90 thousand +5.9%1.5%4.7 $5.24 5/15/2023139,300 shares $866.45 thousand -30.0%1.5%4.1 $6.22 4/30/2023198,900 shares $952.73 thousand +8.6%2.1%5.6 $4.79 4/15/2023183,200 shares $883.02 thousand +12.6%1.9%4.5 $4.82 3/31/2023162,700 shares $811.87 thousand +25.6%1.7%3.2 $4.99 3/15/2023129,500 shares $609.95 thousand -11.2%1.4%1.5 $4.71 2/28/2023145,800 shares $666.31 thousand +9.3%1.5%1.7 $4.57 2/15/2023133,400 shares $729.70 thousand +0.9%1.4%1.6 $5.47 1/31/2023132,200 shares $699.34 thousand +15.9%1.4%1.7 $5.29 1/15/2023114,100 shares $456.40 thousand +117.8%1.2%1.6 $4.00 12/30/202252,400 shares $115.80 thousand -13.8%0.6%0.9 $2.21 12/15/202260,800 shares $234.08 thousand -20.3%0.6%3.6 $3.85 11/30/202276,300 shares $330.00 thousand +14.1%0.8%5 $4.33 11/15/202266,900 shares $278.30 thousand +43.9%0.7%4 $4.16 10/31/202246,500 shares $202.74 thousand +10.2%0.5%2.3 $4.36 10/15/202242,200 shares $200.87 thousand -8.7%0.4%1.8 $4.76 9/30/202246,200 shares $205.13 thousand +9.7%0.5%1.9 $4.44 9/15/202242,100 shares $214.29 thousand +7.4%0.4%1.2 $5.09 8/31/202239,200 shares $225.01 thousand -0.3%0.4%1.1 $5.74 8/15/202239,300 shares $208.29 thousand -13.8%0.4%1 $5.30 7/31/202245,600 shares $177.16 thousand -13.0%0.5%1 $3.89 7/15/202252,400 shares $205.93 thousand -6.4%0.6%0.9 $3.93 6/30/202256,000 shares $179.76 thousand +12.7%0.6%0.8 $3.21 6/15/202249,700 shares $147.61 thousand -41.0%0.5%0.6 $2.97 5/31/202284,200 shares $327.54 thousand +19.9%0.9%1 $3.89 5/15/202270,200 shares $157.25 thousand -50.3%0.7%0.8 $2.24 4/30/2022141,100 shares $530.54 thousand +76.6%1.5%1.8 $3.76 4/15/202279,900 shares $411.49 thousand -48.0%0.8%1.2 $5.15 3/31/2022153,600 shares $872.45 thousand +16.3%1.6%2.4 $5.68 3/15/2022132,100 shares $516.51 thousand -4.4%1.4%2.3 $3.91 2/28/2022138,200 shares $909.36 thousand +4.5%1.5%2.6 $6.58 2/15/2022132,300 shares $1.06 million -17.4%1.4%1.9 $7.98 1/31/2022160,100 shares $1.43 million -27.2%1.9%1.9 $8.96 1/15/2022219,900 shares $2.35 million -9.4%N/A2.3 $10.67 12/31/2021242,600 shares $3.14 million -16.8%2.8%2.6 $12.96 12/15/2021291,500 shares $4.79 million +33.0%3.4%2.5 $16.44 11/30/2021219,200 shares $4.15 million +0.3%2.6%1.4 $18.95 11/15/2021218,500 shares $3.88 million -6.8%2.6%1.5 $17.78 10/29/2021234,400 shares $5.49 million +10.4%2.8%1.6 $23.44 10/15/2021212,300 shares $3.74 million -18.3%2.5%1.4 $17.61 9/30/2021259,900 shares $6.33 million -7.4%3.1%0.5 $24.35 9/15/2021280,700 shares $6.02 million -14.5%3.4%0.6 $21.45 8/31/2021328,400 shares $4.61 million +70.1%4.0%0.8 $14.03 8/13/2021193,100 shares $2.74 million -5.1%2.2%0.4 $14.19 7/30/2021203,400 shares $3.30 million -3.4%2.3%0.5 $16.22 7/15/2021210,600 shares $3.28 million +0.9%2.4%0.5 $15.58The Trump Dump is starting; Get out of stocks now? (Ad)The first 365 days of the Trump presidency… Will be the best time to get rich in American history.If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a 6/30/2021208,700 shares $3.61 million -8.2%2.3%2.2 $17.30 6/15/2021227,400 shares $3.90 million -6.6%2.5%2.5 $17.15 5/28/2021243,500 shares $5.09 million +4.8%2.8%2.6 $20.92 5/14/2021232,400 shares $3.80 million +2.6%2.6%2 $16.33 4/30/2021226,600 shares $6.12 million +18.3%2.7%0.8 $27.03 4/15/2021191,600 shares $5.33 million -19.0%2.4%0.7 $27.83 3/31/2021236,400 shares $7.29 million +20.9%2.9%0.8 $30.84 3/15/2021195,500 shares $5.71 million -9.1%2.5%0.7 $29.20 2/26/2021215,100 shares $8.23 million +199.6%2.7%0.8 $38.24 2/12/202171,800 shares $1.67 million +86.0%0.9%0.3 $23.27 1/29/202138,600 shares $543.87 thousand -4.0%0.5%0.5 $14.09 1/15/202140,200 shares $528.23 thousand No Change0.5%0.7 $13.14 IMNM Short Interest - Frequently Asked Questions What is Immunome's current short interest? Short interest is the volume of Immunome shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 14,210,000 shares of IMNM short. 17.91% of Immunome's shares are currently sold short. Learn More on Immunome's current short interest. What is a good short interest ratio for Immunome? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMNM shares currently have a short interest ratio of 15.0. Learn More on Immunome's short interest ratio. Which institutional investors are shorting Immunome? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Immunome: Group One Trading LLC, Jefferies Financial Group Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Immunome? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.91% of Immunome's floating shares are currently sold short. Is Immunome's short interest increasing or decreasing? Immunome saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 14,210,000 shares, an increase of 0.1% from the previous total of 14,200,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Immunome's float size? Immunome currently has issued a total of 87,040,000 shares. Some of Immunome's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Immunome currently has a public float of 79,320,000 shares. How does Immunome's short interest compare to its competitors? 17.91% of Immunome's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Immunome: Apellis Pharmaceuticals, Inc. (18.71%), MoonLake Immunotherapeutics (11.00%), Protagonist Therapeutics, Inc. (9.74%), Mirum Pharmaceuticals, Inc. (15.41%), Bausch Health Cos Inc. (2.50%), Kymera Therapeutics, Inc. (14.17%), Scholar Rock Holding Corporation (17.84%), Amneal Pharmaceuticals, Inc. (3.42%), Xenon Pharmaceuticals Inc. (9.47%), Crinetics Pharmaceuticals, Inc. (14.66%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Immunome stock? Short selling IMNM is an investing strategy that aims to generate trading profit from Immunome as its price is falling. IMNM shares are trading up $0.35 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Immunome? A short squeeze for Immunome occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IMNM, which in turn drives the price of the stock up even further. How often is Immunome's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMNM, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies Apellis Pharmaceuticals Short Interest Data MoonLake Immunotherapeutics Short Interest Data Protagonist Therapeutics Short Interest Data Mirum Pharmaceuticals Short Interest Data Bausch Health Cos Short Interest Data Kymera Therapeutics Short Interest Data Scholar Rock Short Interest Data Amneal Pharmaceuticals Short Interest Data Xenon Pharmaceuticals Short Interest Data Crinetics Pharmaceuticals Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IMNM) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access